P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015ECCO '16 Amsterdam
2016
P438: The inflammatory bowel disease disability index applied to ileal pouch anal anastomoses in New ZealandECCO '16 Amsterdam
2016
P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease managementECCO '16 Amsterdam
2016
P441: Conjoint analysis for quantification of inflammatory bowel disease patients’ preferences for outcome metricsECCO '16 Amsterdam
2016
P442: Evaluation of safety and efficacy of laparoscopic surgery for ulcerative colitisECCO '16 Amsterdam
2016
P443: National treatment strategy in inflammatory bowel diseases in Hungary: results from the National Health Insurance Fund Prescription DatabaseECCO '16 Amsterdam
2016
P444: High-dose intravenous iron isomaltoside infusion is not associated with an increase in intact fibroblast growth factor 23 (iFGF23) in patients with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P445: Early outcomes for adolescent inflammatory bowel disease patients treated in a transition clinicECCO '16 Amsterdam
2016
P446: Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory ulcerative colitis: experience from a tertiary referral centreECCO '16 Amsterdam
2016
P447: Seasonal variations in Vitamin D concentrations in a single-centre inflammatory bowel disease seriesECCO '16 Amsterdam
2016
P448: IBD nurse in patients’ health status assessment: data from a pilot study comparing ability of IBD nurse and gastroenterologist in using IBD clinical scoresECCO '16 Amsterdam
2016
P449: Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 monthsECCO '16 Amsterdam
2016
P450: A gender comparison of the association between coping strategies and perceived social support in Crohn’s disease patientsECCO '16 Amsterdam
2016
P451: The efficacy of infliximab in tacrolomus non-responder with ulcerative colitisECCO '16 Amsterdam
2016
P452: Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatmentECCO '16 Amsterdam
2016
P453: Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseasesECCO '16 Amsterdam
2016
P454: Combo-therapy in infliximab-resistant inflammatory bowel disease patients: data from a tertiary referral centreECCO '16 Amsterdam
2016